How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Blastocyst Transfer Market
- By Procedure Type: Fresh Blastocyst Transfer, Frozen Blastocyst Transfer, Day 5 Blastocyst Transfer, Day 6 Blastocyst Transfer
- By Indication: Infertility Treatment, Preimplantation Genetic Testing, Donor Egg IVF, Repeated Implantation Failure
- By Patient Age Group: Under 35 Years, 35-40 Years, Above 40 Years
- By End-User: Fertility Clinics, Hospitals, Specialized IVF Centers, Research Institutes
- By Technology: Assisted Hatching, Time-Lapse Imaging, Cryopreservation Techniques, Embryo Culture Media
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Fresh Blastocyst Transfer leads By Procedure Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Blastocyst Transfer Market report
A complete, evidence-based study - 12 chapters and 117 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Procedure Type 4
Indication 4
Patient Age Group 3
End-User 4
Technology 4
Companies profiled
CooperSurgical Inc.
Vitrolife AB
Fujifilm Irvine Scientific
Origio (a CooperSurgical company)
Cook Medical
Genea Biomedx
Merck KGaA (MilliporeSigma)
Hamilton Thorne Ltd.
SAGE Fertility
Irvine Scientific
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →CooperSurgical Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Vitrolife AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Fujifilm Irvine Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Origio (a CooperSurgical company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cook Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Genea Biomedx
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Merck KGaA (MilliporeSigma)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Hamilton Thorne Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →SAGE Fertility
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Irvine Scientific
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →
Global · 2025–2033
$1,609M by 2033 · 5.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Fresh Blastocyst Transfer38.8
- Frozen Blastocyst Transfer20.2
- Day 5 Blastocyst Transfer21.1
- Day 6 Blastocyst Transfer19.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$348.0M → $587.1M · 6.8%
Europe$242.5M → $382.1M · 5.8%
Asia Pacific$221.4M → $374.9M · 6.8%
Latin America$137.1M → $198.3M · 4.7%
Middle East and Africa$105.4M → $156.2M · 5.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.382026
5.392027
5.392028
5.402029
5.422030
5.432031
5.442032
5.462033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- CooperSurgical Inc.14.6
- Vitrolife AB19.1
- Fujifilm Irvine Scientific8.6
- Origio (a CooperSurgical company)11.2
- Cook Medical13.4
- Genea Biomedx5.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Procedure Type14.9%
Indication13.5%
Patient Age Group16.6%
End-User16.0%
Technology39.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.6
- Europe22.5
- Asia Pacific22.1
- Latin America11.7
- Middle East and Africa9.2
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| CooperSurgical Inc. | 86 | 84 | 95 | 93 | 78 | 80 | 86 |
| Vitrolife AB | 84 | 69 | 78 | 68 | 74 | 79 | 75 |
| Fujifilm Irvine Scientific | 64 | 63 | 88 | 77 | 85 | 80 | 76 |
| Origio (a CooperSurgical company) | 80 | 69 | 79 | 69 | 67 | 61 | 71 |
| Cook Medical | 73 | 74 | 63 | 53 | 70 | 63 | 66 |
| Genea Biomedx | 67 | 65 | 64 | 55 | 52 | 50 | 59 |
| Merck KGaA (MilliporeSigma) | 45 | 61 | 43 | 53 | 65 | 44 | 52 |
| Hamilton Thorne Ltd. | 52 | 55 | 53 | 52 | 46 | 51 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- CooperSurgical Inc.
- Vitrolife AB
- Fujifilm Irvine Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| CooperSurgical Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Vitrolife AB | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| Fujifilm Irvine Scientific | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Origio (a CooperSurgical company) | ◐ | ◐ | ✓ | ✓ | ◐ | − |
| Cook Medical | ✓ | ◐ | − | − | ◐ | − |
| Genea Biomedx | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Merck KGaA (MilliporeSigma) | − | ◐ | − | − | ◐ | − |
| Hamilton Thorne Ltd. | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1CooperSurgical Inc.86
2Fujifilm Irvine Scientific76
3Vitrolife AB75
4Origio (a CooperSurgical company)71
5Cook Medical66
6Genea Biomedx59
7Merck KGaA (MilliporeSigma)52
8Hamilton Thorne Ltd.52
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
CooperSurgical Inc.
Challenger3
Strong scale, closing on the leaders.
Vitrolife ABFujifilm Irvine ScientificOrigio (a CooperSurgical company)
Contender2
Focused players with pockets of strength.
Cook MedicalGenea Biomedx
Niche2
Specialists in a single segment or region.
Merck KGaA (MilliporeSigma)Hamilton Thorne Ltd.
Go-to-market strategy
Land Procedure Type in North America, then scale across Blastocyst Transfer Market — a $376M beachhead inside a $4.86B market.
Beachhead (SOM)$376Mobtainable near-term
Serviceable (SAM)$1.99Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Fresh Blastocyst Transfer
Best fit — highest urgency & budget in Procedure Type.
Economic buyer79 fit
Frozen Blastocyst Transfer
Strong fit — clear ROI and a fast path to value.
End user69 fit
Day 5 Blastocyst Transfer
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Procedure Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Age Group
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel27%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Procedure Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blastocyst Transfer Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified20%
Evaluation13%
Closed-won6%
$12.5KCAC
$46KLTV
3.7:1LTV : CAC
< 2 moCAC payback
Investment thesis
Blastocyst Transfer Market is a resilient opportunity — $6.56B by 2033, compounding at 3.7%.
TAM · 2025$4.90Btoday
TAM · 2033$6.56Bforecast
CAGR3.7%2027–2033
Cumulative$51.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.56BTotal addressable market
SAM$2.43BServiceable available market
SOM$465MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.7% CAGR
Demand compounds through 2033, outpacing GDP across Procedure Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Procedure Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.56BLarge & growingTAM by 2033 at 3.7% CAGR
$2.43BServiceable nowreachable with today’s model
$465MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.11BBear2.4% CAGR
$6.56BBase3.7% CAGR
$8.39BBull4.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Blastocyst Transfer Market — a $6.64B market by 2033. Plan: grow share from 8.1% to 17.1%.
Market size · 2033$6.64Btotal addressable
Market CAGR10.9%2027–2033
Target share17.1%from 8.1% today
Revenue ambition$1.14Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.1% | 17.1% | On track |
| Revenue | $574M | $1.14B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.6% | 38.2% | At risk |
| Customer retention | 87.3% | 93.2% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Procedure Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Procedure Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $141M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Procedure Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAhead
- Execution & talentBehind
Sales deck · value proposition
Win the Blastocyst Transfer Market conversation — a $5.31B market you can size, segment and defend in minutes.
Market size · 2033$5.31Btotal opportunity
Growth10.3%CAGR to 2033
Addressable buyers1,404+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Procedure Type
Goal Grow share in Procedure Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 2 mopayback period
$68K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
CooperSurgical Inc.Vitrolife ABFujifilm Irvine ScientificOrigio (a CooperSurgical company)Cook MedicalGenea BiomedxMerck KGaA (MilliporeSigma)Hamilton Thorne Ltd.+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blastocyst Transfer Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blastocyst Transfer Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Blazed Gratings Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportBleach Solution Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportBleach Sulfate Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportBleached Broadleaf Pulp Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportBleached Chemi-ThermoMechanical Pulp Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportBleached Pulp Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportBleached Sulphite Pulp Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportBleaching Lamp In Dental Practice Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportBleaching Stabilizer Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportBleeding Control Kit Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportBleeding Disorders Therapeutics Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportBleeding Toothpastes Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.